Comparison of two kinds of nanomedicine for targeted gene therapy: premodified or postmodified gene delivery systems

Figures & data

Figure 1 General reaction scheme for synthesis of MN-PEG-PE.

Abbreviations: DMSO, dimethylsulfoxide; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine; TEA, triethylamine.

Figure 2 Preparation of pre- (A) and post- (B) MN-PEG-PE-modified SLN/DNA.

Abbreviations: SLN, solid lipid nanoparticles; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine; A-MN-SLNs/DNA, pre-MN-PEG-PE-modified SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA.

Figure 3 Optimization of the modification ratios for (A) pre-MN-PEG-PE-modified SLN/DNA and (B) post-MN-PEG-PE-modified SLN/DNA.

Abbreviations: SLN, solid lipid nanoparticles; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine.

Table 1 Particle size and zeta potential of different vectors

Characteristics/samples	Mean particle size (nm)	Polydispersity index	Zeta potential (mV)
SLN	87.5 ± 5.2	0.11 ± 0.02	+45.2 ± 1.5
MN-SLN	153.1 ± 4.3	0.20 ± 0.02	+28.5 ± 2.3
SLN/DNA	121.8 ± 5.8	0.15 ± 0.03	+33.1 ± 2.4
Pre-MN-PEG-PE-modified SLN/DNA	223.6 ± 5.3	0.22 ± 0.05	+20.4 ± 2.1
Post-MN-PEG-PE-modified SLN/DNA	185.2 ± 4.1	0.11 ± 0.04	+21.3 ± 1.7

Abbreviations: SLN, solid lipid nanoparticles; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine.

Figure 4 Con A agglutination assay of different vectors.

Abbreviations: SLN, solid lipid nanoparticles; A-MN-SLNs/DNA, pre-MN-PEG-PE-modified SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine.

Figure 5 Viability of Kupffer cells targeted with A-MN-SLN/DNA and B-MN-SLN/DNA.

Abbreviations: SLN, solid lipid nanoparticles; A-MN-SLNs/DNA, pre-MN-PEG-PE-modified SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine.

Figure 6 In vitro release profiles of A-MN-SLN/DNA and B-MN-SLN/DNA.

Abbreviations: SLN, solid lipid nanoparticles; A-MN-SLNs/DNA, pre-MN-PEG-PE-modified SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine; pEGFP, plasmid-enhanced green fluorescent protein.

Figure 7 In vitro transfection efficiency of A-MN-SLN/DNA and B-MN-SLN/DNA in Kupffer cells after transfection for 24, 48, and 72 hours.

Abbreviations: SLN, solid lipid nanoparticles; A-MN-SLNs/DNA, pre-MN-PEG-PE-modified SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine.

Figure 8 Fluorescent images of Kupffer cells transfected with naked pEGFP (A), SLN/DNA (B), PEG-PE-SLN/DNA (C), A-MN-SLN/DNA (D), and B-MN-SLN/DNA (E) at 24, 48, and 72 hours after transfection.

Abbreviations: SLN, solid lipid nanoparticles; A-MN-SLNs/DNA, pre-MN-PEG-PE-modified SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine; pEGFP, plasmid-enhanced green fluorescent protein.

Figure 9 In vivo transfection efficiency of A-MN-SLN/DNA and B-MN-SLN/DNA in Kupffer cells after transfection for 24, 48, and 72 hours.

Abbreviations: SLN, solid lipid nanoparticles; A-MN-SLNs/DNA, pre-MN-PEG-PE-modified SLN/DNA; B-MN-SLNs/DNA, post-MN-PEG-PE-modified SLN/DNA; MN, mannan; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine.